ArticleEpilepsia2008
Early treatment suppresses the development of spike-wave epilepsy in a rat model.
Article in Epilepsia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 205 citations in OpenAlex.
- Historical trend toward improved long-term outcome in childhood absence epilepsy.Epilepsy research · 2019Pooled it
- Treatment in canine epilepsy--a systematic review.BMC veterinary research · 2014Pooled it
- Trial
- Photothrombosis-induced cortical stroke mouse model produces focal electrographic epileptic human biomarkers.Experimental neurology · 2026Article
- Behavioral Phenotyping of WAG/Rij Rat Model of Absence Epilepsy: The Link to Anxiety and Sex Factors.Biomedicines · 2025Article
- The Diagnostic Value of EEG Wave Trains for Distinguishing Immature Absence Seizures and Sleep Spindles: Evidence from the WAG/Rij Rat Model.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Review
- The role of HCN channels on the effects of T-type calcium channels and GABAPflugers Archiv : European journal of physiology · 2024Article
- Tactile stimulation of young WAG/Rij rats prevents development of depression but not absence epilepsy.Frontiers in behavioral neuroscience · 2024Article
- Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs.International journal of molecular sciences · 2023Review
- Maternal Methyl-Enriched Diet Increases DNMT1, HCN1, and TH Gene Expression and Suppresses Absence Seizures and Comorbid Depression in Offspring of WAG/Rij Rats.Diagnostics (Basel, Switzerland) · 2023Article
- Alpha2-Adrenergic Receptors as a Pharmacological Target for Spike-Wave Epilepsy.International journal of molecular sciences · 2023Review
- Adrenergic mechanisms of absence status epilepticus.Frontiers in neurology · 2023Review
- The impact of early-life environment on absence epilepsy and neuropsychiatric comorbidities.IBRO neuroscience reports · 2022Review
- Maladaptive myelination promotes generalized epilepsy progression.Nature neuroscience · 2022Article
- Critical periods inFrontiers in physiology · 2022Review
- Neural Burst Firing and Its Roles in Mental and Neurological Disorders.Frontiers in cellular neuroscience · 2021Article
- TheFrontiers in neural circuits · 2021Review
- Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures.Brain : a journal of neurology · 2020Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeCurrent treatments for epilepsy may control seizures, but have no known effects on the underlying disease. We sought to determine whether early treatment in a model of genetic epilepsy would reduce the severity of the epilepsy phenotype in adulthood.
methodsWe used Wistar albino Glaxo rats of Rijswijk (WAG/Rij) rats, an established model of human absence epilepsy. Oral ethosuximide was given from age p21 to 5 months, covering the usual period in which seizures develop in this model (age approximately 3 months). Two experiments were performed: (1) cortical expression of ion channels Nav1.1, Nav1.6, and HCN1 (previously shown to be dysregulated in WAG/Rij) measured by immunocytochemistry in adult treated rats; and (2) electroencephalogram (EEG) recordings to measure seizure severity at serial time points after stopping the treatment.
resultsEarly treatment with ethosuximide blocked changes in the expression of ion channels Nav1.1, Nav1.6, and HCN1 normally associated with epilepsy in this model. In addition, the treatment led to a persistent suppression of seizures, even after therapy was discontinued. Thus, animals treated with ethosuximide from age p21 to 5 months still had a marked suppression of seizures at age 8 months. DISCUSSION: These findings suggest that early treatment during development may provide a new strategy for preventing epilepsy in susceptible individuals. If confirmed with other drugs and epilepsy paradigms, the availability of a model in which epileptogenesis can be controlled has important implications both for future basic studies, and human therapeutic trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.